New York, New York–(Newsfile Corp. – January 13, 2025)– Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of shares of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant to and/or traceable to BioAge's initial public offering conducted on September 26, 2024 (the “IPO”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the court No later than March 10, 2025.
so what: If you purchase BioAge shares, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
What to do next: To join the BioAge class action, go to https://rosenlegal.com/submit-form/?case_id=33167 or contact Phillip Kim, Esq. Toll free is 866-767-3653 or email case@rosenlegal.com for information about the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the court No later than March 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the lawsuit.
Why Rosen's Law: We encourage investors to select qualified advisors with a proven track record of success in leadership roles. Often, companies issuing notices do not have similar experience, resources, or any meaningful recognition from their peers. Be wise in choosing advisors. The Rosen Law Firm represents investors throughout the world, focusing its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever settlement of a securities class action lawsuit against a Chinese company at that time. Rosen Law Firm has been ranked #1 in the ISS Securities Class category an act (WA:) Services for a number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company raised more than $438 million for investors. In 2020, co-founder Lawrence Rosen was named by Law360 as a Titan in the Plaintiffs Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Case details: According to the lawsuit, the defendants promoted their lead product candidate azelaprag in connection with the ongoing clinical trial of BioAge STRIDES with key results expected in 2025. The defendants also mentioned their collaboration with the Eli Lilly and Company (NYSE:) (“Lilly”) development organization Clinical staff who will provide advice and assistance in all aspects of the design and implementation of the STRIDES trial. The defendants also discussed the possibility of conducting a second Phase 2 clinical trial combining azalaprague with semaglutide for the treatment of obesity in individuals 18 years of age and older. Therefore, the IPO made it clear to the public that there are no safety concerns and that BioAge expects high results and to achieve its primary end goals for its STRIDES clinical trial.
Contrary to these claims, BioAge halted the STRIDES phase 2 study of its investigational drug candidate azelaprag after several people showed elevated levels of liver enzymes warning of potential organ damage. As a result, the defendants halted the clinical trial and halted further registration. Due to the fact that Defendants failed to disclose the potential for amino-hepatitis in any of their prior Phase I clinical trials and various preclinical toxicology studies, Defendants' statements in BioAge's registration statement were false and/or materially misleading at the time of the IPO. When the true details entered the market, the lawsuit claims, investors suffered damages.
To join the BioAge class action, go to https://rosenlegal.com/submit-form/?case_id=33167 or contact Phillip Kim, Esq. Toll free is 866-767-3653 or email case@rosenlegal.com for information about the class action.
No category is approved. Until the class is approved, you will not be represented by counsel unless you retain one. You can choose the lawyer of your choice. You can also remain an absent class member and do nothing at this point. An investor's ability to participate in any potential future recovery is not dependent on serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https: //www.facebook.com/rosenlawfirm/.
Lawyer advertisement. Previous results do not guarantee a similar result.
—————————-
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237075
